Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Diagnosis of granulomatous inflammation in thoracic small biopsies and fine needle aspiration specimens: a multi-institutional study.

Journal of the American Society of Cytopathology·2026
Same author

Patient-reported outcomes in castration-resistant prostate cancer with bone metastases treated with radium-223 with or without olaparib.

Cancer·2026
Same author

A plain language summary of the final overall survival results from the TALAPRO-2 study comparing talazoparib plus enzalutamide versus placebo plus enzalutamide for patients with advanced prostate cancer and changes in specific DNA repair genes.

Future oncology (London, England)·2026
Same author

Critical role of keratinocytes and protease-activated receptor 2 in secondary lymphedema development.

Clinical and translational medicine·2026
Same author

PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.

The New England journal of medicine·2026
Same author

Multicenter, Randomized, Phase II Trial of Olaparib Plus Radium-223 Versus Radium-223 in Men With Castration-Resistant Prostate Cancer With Bone Metastases (COMRADE).

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026

相关实验视频

Updated: Sep 9, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.1K

间歇性talazoparib加temozolomide的1b/ 2期研究在转移性割抗性前列腺癌患者中,并且没有DNA损伤响应基因突变

Karen A Autio1, Christos E Kyriakopoulos2, Paul Palyca3

  • 1Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA. autiok@mskcc.org.

Investigational new drugs
|September 4, 2025
PubMed
概括

在没有HRR变化的转移性割抗性前列腺癌患者中,结合talazoparib和temozolomide的疗效有限,血液毒性显著. 由于其风险/ 益处概况,该组合策略不支持进一步的临床评估.

关键词:
化学疗法一种PARP抑制剂前列腺癌塔拉佐帕里布

更多相关视频

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

相关实验视频

Last Updated: Sep 9, 2025

Evaluating In Vitro DNA Damage Using Comet Assay
10:43

Evaluating In Vitro DNA Damage Using Comet Assay

Published on: October 11, 2017

38.1K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.2K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.4K

科学领域:

  • 癌症学
  • 药理学
  • 生殖和尿道癌症

背景情况:

  • 在没有同源复合修复 (HRR) 改变的瘤中,多 (ADP- 核糖) 聚合酶抑制剂 (PARP) 的单一疗效有限.
  • 临床前数据表明,将PARP抑制剂与化疗结合使用可以增强DNA损伤和瘤反应.

研究的目的:

  • 在没有HRR变化的转移性抵抗性前列腺癌 (mCRPC) 患者中评估talazoparib加temozolomide的安全性和有效性.
  • 确定该组合治疗的最大耐受剂量 (MTD) 和建议的第二阶段剂量 (RP2D).

主要方法:

  • 一个阶段1b/ 2试验招募了前期失败的mCRPC患者.
  • 患者接受了不断增加的talazoparib和temozolomide剂量以确定MTD和RP2D.
  • 使用包括客观反应,前列腺特异性抗原 (PSA) 降低和循环瘤细胞 (CTC) 转换在内的复合终点来评估疗效.

主要成果:

  • 确定了MTD,并确定了RP2D,即在28天周期中,talazoparib为1mgQD (D1- 6) 和temozolomide为75mg/ m2QD (D2- 8).
  • 最常见的不良反应包括血小板减小,中性质减小,贫血,疲劳和恶心.
  • 血液毒性,特别是中性衰竭发烧和血小板减少,是剂量限制的.
  • 在16名患者中,只有3名 (18. 8%) 达到综合疗效终点.
  • 由于风险/ 益处概况不利,该试验的第二阶段提前结束.

结论:

  • 在没有HRR变化的mCRPC患者中,talazoparib与temozolomide的组合显示出显著的血液毒性.
  • 观察到的疗效有限,毒性概况不支持进一步研究这种间歇性剂量策略.